Welcome : Guest

Chimerix, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Chimerix, Inc., which is principally involved in Biopharmaceuticals Business. Illustrated with 26 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-64024
Price: $1300
Company Type: Public
Pages: 28
Date: November 2016
Market Data Tables: 26

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Stem Cell Transplantation......3
Table 1: Stem Cell Transplantation Market by Category for American Indian and Alaskan Natives in the US (2015) - Percentage Market Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......3
Table 2: Stem Cell Transplantation Market by Category for Asians in the US (2015) - Percentage Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......4
Table 3: Stem Cell Transplant Market by Category for Black and African Americans in the US (2015) - Percentage Market Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......5
Table 4: Stem Cell Transplantation Market by Category for Native Hawalian and Other Pacific Islanders in the US (2015) - Percentage Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......6
Table 5: Stem Cell Transplantation Market by Category for Whites in the US (2015) - Percentage Share Breakdown by Volume for Bone Marrow of Periperal Blood and Cord Blood......7
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)......8
Table 6: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Acute Leukemia by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......8
Table 7: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Bone Marrow Failure by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......9
Table 8: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Leukemia by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......10
Table 9: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Leukemias by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......11
Table 10: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Lymphoma by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......12
Table 11: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Lymphoproliferative by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......13
Table 12: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Mixed Myelodysplastic and Myeloproliferative Syndromes (MDS/MPS) by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......14
Table 13: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Non-Malignant Disorders by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......15
Table 14: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Plasma Cell Disorders by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......16
Table 15: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Solid Tumors by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Americas, Europe and Others......17
Table 16: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Market by Category in Americas (2015) - Percentage Share Breakdown by Value for Acute Leukemia, Chronic Leukemia, Leukemias, Lymphoma, Lymphoproliferative, Mixed Myelodysplastic and Myeloproliferative Syndromes (MDS/MPS) and Others......18
Table 17: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Market by Category in Europe (2015) - Percentage Share Breakdown by Value for Acute Leukemia, Leukemias, Lymphoma, Lymphoproliferative, Mixed Myelodysplastic and Myeloproliferative Syndromes (MDS/MPS), Non-Malignant Disorders and Others......19
Table 18: Number of β-thalassemia Patients for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) by Category in Europe (2015) - Percentage Market Share Breakdown by Volume for Bone Marrow (BM), Mixed Chimerism, Peripheral Blood (PB), Unrelated Cord Blood Transplantation (UCB) and Uterine Natural Killer (UNK)......20
Haematopoietic Stem Cell Transplantation (HSCT)......21
Table 19: Haematopoietic Stem Cell Transplantation (HSCT) Market by Region Worldwide (2015) - Percentage Share Breakdown by Volume for European Union, United States and Rest Of World......21
Antivirals......22
Table 20: Antiviral Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Antiviral Drugs, Monoclonal Antibodies, Vaccines and Others......22
HIV Drugs......23
Table 21: HIV Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)/ Nucleoside Reverse Transcriptase Inhibitor (NRTI) Fixed Dose Combination (FDC), Nucleoside Reverse Transcriptase Inhibitor (NRTI)/Retroviral Integrase/CYP3A, Nucleoside Reverse Transcriptase Inhibitor (NRTIs), Protease Inhibitors, Retroviral Integrase (IN), and Others* (Includes NNRTIs)......23
Table 22: HIV Regimens for New Start Patients by Segment in European Union (2015) - Percentage Market Share Breakdown by Value Sales for Atripla, Compler, Stribild, Truvada and Others......24
Table 23: HIV Regimens for Experienced Patients by Segment in the US (2015) - Percentage Market Share Breakdown by Value Sales for Atripla, Stribild, Truvada and Others......25
Table 24: HIV Regimens for New Start Patients by Segment in the US (2015) - Percentage Market Share Breakdown by Value Sales for Atripla, Compler, Stribild, Truvada and Others......26
HBV/HCV Therapeutics......27
Table 25: Market Shares of Leading HBV/HCV Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., and Others......27
Table 26: Market Shares of Leading Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Bristol-Myers Squibb Co (BMY), GlaxoSmithKline Plc (GSK), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Vertex Pharmaceuticals, Inc. (VRTX), and Others......28